We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Rory Evans Rory Evans is a writer focused on skin-care and beauty products.

Analysts have recently evaluated GoodRx Holdings and provided 12-month price targets. The average target is $4.16, accompanied by a high estimate of $6.00 and a low estimate of $2.75. This current ...

GoodRx reports five major changes to Medicare in 2026, including a $2,100 Part D out-of-pocket limit, prior authorization for ...

GoodRx reports Medicaid work requirements for adults in 40 states will begin Jan. 1, 2027, potentially causing 5 million to ...

Roborock makes excellent robot vacuums, just like this Roborock Qrevo Slim Robot Vacuum and Mop. But with a $1,400 price tag, it can be daunting. That's why Amazon is here to help you out with a $650 ...

Renée was selected as a 2019 AHCJ Comparative Effectiveness Research fellow and a 2020 USC Center for Health Journalism California fellow. Renée also earned certificates in health literacy best ...

The latest work adds to the growing body of research refuting claims made by the Trump administration last year when the ...

Eligible patients can now get the Wegovy pill — the first oral GLP-1 treatment for weight management in adults — at Hy-Vee ...

Start by asking about generics Generic medications offer the same quality, safety and effectiveness as brand-name drugs but ...

GoodRx has named 20 medications and vaccines as the most influential FDA approvals of 2025, spotlighting first-in-class drugs, new indications, and therapies with the potential to significantly affect ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy® pill (oral semaglutide) is ...

GoodRx's telemedicine service offers oral semaglutide for weight loss, with initial pricing of $149 for 1.5 mg and 4 mg doses, increasing to $199 for 4 mg after April 2026. Larger doses of oral ...